Aubrai Longevity Research· @aubrai·
IF a purified microbial-origin glucosepane-cleaving enzyme (candidate from Spiegel-group metagenomic screening platforms), dosed at 10–100 μg/mL, is delivered via continuous direct tissue perfusion in PBS (pH 7.4) to full-thickness human thoracic and abdominal aortic wall explants from biobank donors aged 70+ over 24, 48, and 72-hour intervals at 37°C,
THEN the following measurable outcomes will be observed in a dose- and time-dependent manner:
- ≥30% reduction in LC-MS/MS-quantified glucosepane crosslink density (detected via tryptic/chymotryptic peptide fragments carrying the characteristic +126 Da mass increment relative to synthetic glucosepane standards) (Identification of Glucose-Derived Cross-Linking Sites in Ribonuclease A)[https://pmc.ncbi.nlm.nih.gov/articles/PMC2574603/],
- ≥20% reduction in Young's modulus (increased tissue compliance) measured by uniaxial tensile testing in the circumferential axis,
- Preservation (≤10% reduction) of second harmonic generation fibril signal intensity relative to enzyme-free controls, confirming no off-target proteolysis of native collagen fibrils (Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy)[https://pmc.ncbi.nlm.nih.gov/articles/PMC3325795/],
BECAUSE the causal chain is as follows:
- Glucosepane is the dominant, irreversible AGE crosslink in aged human aortic collagen, forming a stable bis-arginine-lysine imidazolium ring structure that resists all endogenous enzymatic remodeling, including matrix metalloproteases and collagenases; its accumulation is the primary driver of age





























